Summary
Thermo Fisher Scientific Inc. reported strong revenue growth of 15% for the fiscal year ended December 30, 2022, reaching $44.9 billion. However, GAAP operating income and diluted EPS saw a decline of 16% and 9% respectively, year-over-year, largely due to reduced COVID-19 testing volumes and strategic growth investments. The company's organic revenue growth was flat (0%) for the year, indicating a normalization after significant pandemic-related demand. The Life Sciences Solutions and Specialty Diagnostics segments experienced revenue declines, primarily driven by decreased demand for COVID-19 related products. Conversely, the Analytical Instruments and Laboratory Products and Biopharma Services segments demonstrated robust growth. The company continues to execute its three-pillar growth strategy: developing innovative products, leveraging scale in high-growth markets, and delivering a unique value proposition. Despite the headwinds from lower COVID-19 demand, Thermo Fisher maintains a strong financial position with robust free cash flow generation of $6.9 billion. The company also remains committed to capital allocation through share repurchases and dividends, with $1 billion authorized for future repurchases as of February 23, 2023.
Financial Highlights
56 data points| Revenue | $44.91B |
| R&D Expenses | $1.47B |
| SG&A Expenses | $8.99B |
| Operating Expenses | $36.52B |
| Operating Income | $8.39B |
| Interest Expense | $726.00M |
| Net Income | $6.95B |
| EPS (Basic) | $17.75 |
| EPS (Diluted) | $17.63 |
| Shares Outstanding (Basic) | 392.00M |
| Shares Outstanding (Diluted) | 394.00M |
Key Highlights
- 1Total revenues increased by 15% to $44.9 billion in 2022.
- 2Organic revenue growth was flat (0%) in 2022, reflecting a normalization of demand post-pandemic, particularly a significant decrease in COVID-19 related product sales ($3.11 billion in 2022 vs. $7.26 billion in 2021).
- 3GAAP operating income decreased by 16% to $8.4 billion, and GAAP diluted EPS decreased by 9% to $17.63, impacted by lower COVID-19 testing volumes and strategic investments.
- 4The Life Sciences Solutions and Specialty Diagnostics segments saw revenue declines of 13% and 16% organically, respectively, primarily due to reduced COVID-19 testing demand.
- 5The Analytical Instruments segment grew organically by 9%, and the Laboratory Products and Biopharma Services segment grew organically by 51%, driven by strong demand in various sub-segments.
- 6Free cash flow remained strong, increasing to $6.9 billion in 2022, supporting capital allocation strategies.
- 7The company repurchased $3.0 billion of its common stock in Q4 2022 and authorized an additional $4.0 billion for future repurchases in November 2022, with $1.0 billion available as of February 23, 2023.